Aspen Pharmacare Holdings (JSE:APN) Beneish M-Score: -2.66 (As of Jun. 25, 2026)


JSE:APN Aspen Pharmacare Holdings Ltd JSE:APN
73 GF Score
Price R151.70
GF Value R178.18
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings Beneish M-Score?

Aspen Pharmacare Holdings JSE:APN +0.26% 73 Beneish M-Score is -2.66 as of Jun. 25, 2026. GuruFocus rates JSE:APN with a GF Score™ of 73/100 and a GF Value™ of R178.18 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 911 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks better than 64.43% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Aspen Pharmacare Holdings's Beneish M-Score or its related term are showing as below:

JSE:APN' s Beneish M-Score Range Over the Past 10 Years
Min: -2.69   Med: -2.44   Max: -2.24
Current: -2.66

During the past 13 years, the highest Beneish M-Score of Aspen Pharmacare Holdings was -2.24. The lowest was -2.69. And the median was -2.44.


Aspen Pharmacare Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Aspen Pharmacare Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspen Pharmacare Holdings Beneish M-Score Chart

Aspen Pharmacare Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.69 -2.33 -2.33 -2.53 -2.66

Aspen Pharmacare Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.53 0.00 -2.66 0.00

JSE:APN vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspen Pharmacare Holdings Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Beneish M-Score falls into.


JSE:APN
73GF Score
Aspen Pharmacare Holdings Ltd JSE:APN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspen Pharmacare Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aspen Pharmacare Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0853+0.528 * 0.9864+0.404 * 1.0373+0.892 * 0.97+0.115 * 0.9996
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1112+4.679 * -0.045933-0.327 * 1.0142
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun25) TTM:Last Year (Jun24) TTM:
Total Receivables was R12,069 Mil.
Revenue was R43,363 Mil.
Gross Profit was R19,129 Mil.
Total Current Assets was R38,702 Mil.
Total Assets was R135,893 Mil.
Property, Plant and Equipment(Net PPE) was R21,707 Mil.
Depreciation, Depletion and Amortization(DDA) was R2,089 Mil.
Selling, General, & Admin. Expense(SGA) was R5,458 Mil.
Total Current Liabilities was R17,496 Mil.
Long-Term Debt & Capital Lease Obligation was R31,508 Mil.
Net Income was R-1,083 Mil.
Gross Profit was R0 Mil.
Cash Flow from Operations was R5,159 Mil.
Total Receivables was R11,465 Mil.
Revenue was R44,706 Mil.
Gross Profit was R19,454 Mil.
Total Current Assets was R44,086 Mil.
Total Assets was R139,063 Mil.
Property, Plant and Equipment(Net PPE) was R20,510 Mil.
Depreciation, Depletion and Amortization(DDA) was R1,973 Mil.
Selling, General, & Admin. Expense(SGA) was R5,064 Mil.
Total Current Liabilities was R24,302 Mil.
Long-Term Debt & Capital Lease Obligation was R25,141 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12069 / 43363) / (11465 / 44706)
=0.278325 / 0.256453
=1.0853

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(19454 / 44706) / (19129 / 43363)
=0.435154 / 0.441136
=0.9864

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (38702 + 21707) / 135893) / (1 - (44086 + 20510) / 139063)
=0.555466 / 0.535491
=1.0373

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=43363 / 44706
=0.97

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1973 / (1973 + 20510)) / (2089 / (2089 + 21707))
=0.087755 / 0.087788
=0.9996

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5458 / 43363) / (5064 / 44706)
=0.125868 / 0.113273
=1.1112

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((31508 + 17496) / 135893) / ((25141 + 24302) / 139063)
=0.360607 / 0.355544
=1.0142

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1083 - 0 - 5159) / 135893
=-0.045933

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aspen Pharmacare Holdings has a M-score of -2.66 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.66 mean?
Aspen Pharmacare Holdings (JSE:APN) has a Beneish M-Score of -2.66 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aspen Pharmacare Holdings and its competitors. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #324 out of 911 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Aspen Pharmacare Holdings' Beneish M-Score too high?
Aspen Pharmacare Holdings' current Beneish M-Score is -2.66. Based on the distribution chart, Aspen Pharmacare Holdings ranks #324 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #324 out of 911 companies for Beneish M-Score. This puts Aspen Pharmacare Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aspen Pharmacare Holdings and its competitors. Aspen Pharmacare Holdings's current Beneish M-Score is -2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R178.18, compared to a current price of R151.70 — trading 14.9% below its estimated fair value. The current Beneish M-Score is -2.66. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Beneish M-Score is -2.66 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of R151.70 is trading 14.9% below its estimated GF Value™ of R178.18. GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.

Key valuation signals for JSE:APN:

  • Beneish M-Score: -2.66
  • GF Value™: R178.18 vs. price of R151.70 (14.9% below fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score

Get the complete analysis for JSE:APN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R151.70
Price
R178.18
GF Value